| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2464b5fae289d36e5d5d39f6c5100dd1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a56d79dd10b040e05c2e6fd6986b18a6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d452ebbe234b18c80d0462dc24578da3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16762
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5254
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-552
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16734
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16771 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-22 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-245 |
| filingDate |
2011-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_700f48c341e9b3521168e50d64fb01b1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1a29411c480a7313be6cfa137b053b4 |
| publicationDate |
2014-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8877211-B2 |
| titleOfInvention |
Bovine herpes virus vaccine with multiple mutations |
| abstract |
A BHV-1 mutant virus has been made that incorporates into a single virus two or more deletions in one or more of three genes—glycoprotein N, glycoprotein E and Us9. Specifically, a BHV-1 U L 49.5Δ30-32 CT-null virus was made and tested. This mutant virus was then used to incorporate additional changes, e.g., the glycoprotein E cytoplasmic-tail deletion, the Us9 deletion, or both. This triple mutant BHV-1 U L 49.5Δ30-32 CT-null/gE CTΔ/Us9Δ virus will be superior to the current BHV-1 mutants because the mutant virus will not be shed following reactivation, will be a DIVA based on gE CT-specific serum antibodies, and will induce better protective response by inducing higher SN titers and better cellular immune response. This new virus will have sufficient viral replication in the nasal epithelium and will be a good vaccine for protection of cattle from BHV-1. The new mutant viruses can also be used as vectors for exogenous genes. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11083787-B2 |
| priorityDate |
2011-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |